- Home
- LVLU vs RPTX Comparison
LVLU vs RPTX Comparison
Compare LVLU & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | RPTX |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1M | 92.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LVLU | RPTX |
|---|---|---|
| Price | $5.65 | $2.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $15.00 | $3.00 |
| AVG Volume (30 Days) | 21.8K | ★ 1.4M |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $285,413,000.00 | $11,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.53 | $3,233.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.98 | $0.89 |
| 52 Week High | $17.40 | $2.66 |
Technical Indicators
Market Signals| Indicator | LVLU | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.14 | 72.78 |
| Support Level | $5.02 | $2.56 |
| Resistance Level | $5.66 | $2.66 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 76.39 | 83.50 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.